Potential crosstalk between cofilin-1 and EGFR pathways in cisplatin resistance of non-small-cell lung cancer.

Abstract

Current challenge in oncology is to establish the concept of personalized medicine in clinical practice. In this context, non-small-cell lung cancer (NSCLC) presents clinical, histological and molecular heterogeneity, being one of the most genomically diverse of all cancers. Recent advances added Epidermal Growth Factor Receptor (EGFR) as a predictive biomarker for patients with advanced NSCLC. In tumors with activating EGFR mutations, tyrosine kinase inhibitors (TKI) are indicated as first-line treatment, although restricted to a very small target population. In this context, cofilin-1 (a cytosolic protein involved with actin dynamics) has been widely studied as a biomarker of an aggressive phenotype in tumors, and overexpression of cofilin-1 is associated with cisplatin resistance and poor prognosis in NSCLC. Here, we gather information about the predictive potential of cofilin-1 and reviewed the crosstalk between cofilin-1/EGFR pathways. We aimed to highlight new perspectives of how these interactions might affect cisplatin resistance in NSCLC. We propose that cofilin-1 quantification in clinical samples in combination with presence/absence of EGFR mutation could be used to select patients that would benefit from TKI's treatment. This information is of paramount importance and could result in a possibility of guiding more effective treatments to NSCLC patients.

• Authors: Carolina Beatriz Müller, Marco Antônio De Bastiani, Matheus Becker, Fernanda Stapenhorst França, Mariane Araujo Branco, Mauro Antônio Alves Castro, Fabio Klamt
• Journal: Oncotarget (Oncotarget) Vol. 6 Issue 6 Pg. 3531-9 (Feb 28 2015) ISSN: 1949-2553 [Electronic] United States
• PMID: 25784483 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cofilin 1
• ErbB Receptors
• Cisplatin

Topics

• Animals
• Carcinoma, Non-Small-Cell Lung (drug therapy, metabolism)
• Cell Line, Tumor
• Cisplatin (pharmacology)
• Cofilin 1 (metabolism)
• Drug Resistance, Neoplasm
• ErbB Receptors (metabolism)
• Humans
• Lung Neoplasms (drug therapy, metabolism)
• Mice
• Signal Transduction